
Investment platform provider CommSec has released data on the five most traded ASX shares on its platform from last week.
There were a number of familiar names in the list this week, but also one which may come as a big surprise to investors.
Here’s the data:
CSL Limited (ASX: CSL)
The biotherapeutics company was the most traded share on the CommSec platform last week and accounted for 2.4% of total trades. This followed the release of its full year results for FY 2020 which revealed a 10% increase in net profit after tax to US$2.1 billion. The buy and selling was relatively even, with 55% of trades from the buy side. The CSL share price rose 6% over the period.
Mesoblast limited (ASX: MSB)
Mesoblast shares were popular with investors last week and accounted for 2% of total trades on the CommSec platform. The biotech company’s shares have been on the move this month following its successful meeting with the U.S. FDA. The regulatory agency’s advisory panel backed its Ryoncil treatment at the meeting, paving the way for approval later this year. Approximately 51% of trades were from buyers last week.
Hydrix Ltd (ASX: HYD)
A surprise entry to the top five was Hydrix. The medical device company’s shares accounted for 1.7% of trades by CommSec investors over the period, with 59% of them coming from buyers. Early buyers did extremely well, with the Hydrix share price recording a 411% gain last week. Investors were buying its shares amid news of four successful implants of its AngelMed Guardian product. This product the world’s first FDA approved implantable heart attack warning system.
Commonwealth Bank of Australia (ASX: CBA)
Australia’s largest bank was popular with investors again and accounted for 1.7% of trades on the CommSec platform. A massive 79% of these trades came from buyers, which appears to indicate that they were pleased with its full year results from the week before.
Zip Co Ltd (ASX: Z1P)
This buy now pay later provider is back in the top five after accounting for 1.5% of trades on the platform last week. However, on this occasion there was more selling than buying going on. Approximately 52% of these trades came from the sell side. Though, this didn’t stop the Zip Co share price from recording another weekly gain. Those buyers will be celebrating today after its shares rocketed to a record high.
Man who said buy Kogan shares at $3.63 says buy these 3 ASX stocks now
When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
In this FREE STOCK REPORT, Scott just revealed what he believes are the 3 ASX stocks for the post COVID world that investors should buy right now while they still can. These stocks are trading at dirt-cheap prices and Scott thinks these could really go gangbusters as we move into ‘the new normal’.
Find out the names of our 3 Post COVID Stocks – For FREE!
*Returns as of 6/8/2020
More reading
- If you invested $10,000 into Zip shares in March, here’s how much you’d have today
- How to boost your share market gains
- Flexigroup share price in trade halt ahead of capital raise
- Why Bigtincan, Cleanaway, Worley, & Zip Co shares are storming higher
- Zip share price surges 20% on eBay partnership
James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of ZIPCOLTD FPO. The Motley Fool Australia owns shares of and has recommended Telstra Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
The post Hydrix and Zip were among the most traded shares on the ASX last week appeared first on Motley Fool Australia.
from Motley Fool Australia https://ift.tt/31ufoMg
Leave a Reply